no news_id given

Clinical Trial, GermanyGermany


Apogenix GmbH (Heidelberg) has initiated a Phase II proof-of-concept study with its lead compound AGP101 + radiotherapy (vs radiotherapy alone) in 83 patients with Glioblastoma Multiforme (GBM). The clinical trial, which is...

Clinical Trial, UK


Funxional Therapeutics Ltd (Cambridge, UK) has completed the Phase I programme of its anti-inflammatory compound FX125L, which belongs to the therapeutic class of Broad-Spectrum Chemokine Inhibitors (BSCIs). In its second safety...

Clinical Trial


The EMA has finished its review of the benefits and risks of taking Biogen Idec and Elan’s multiple sclerosis drug natali­zumab (Tysabri) after 23 (14 EU, thereof 1 death) cases of potentially deadly brain infections with the JC...

Politics / Law


London – The European Medicines Agency (formerly EMEA, now EMA) reported in January that it is adapting its organisational structure to its increasing workload and interactions with patient and consumer organisations. Human pre-...

Politics / Law


GM rice looks set to arrive on plates in China within the next few years following a decision by the Chinese Agriculture Ministry’s bio­safety panel. Made up of 78 high-ranking experts, the panel has for the first time ever...



Dr. Peter Heinrich has joined medical device company Magforce Nanotechnologies AG (Berlin) as Chief Executive Officer after former CEO Dr. Uwe Maschek chose to step down at the end of 2009. Heinrich co-founded MediGene AG, and...

BioPeople, UKUK


Optos plc (London) has announced two changes in its management team. Dr. Peter Fellner has taken the helm at the retinal imaging company after Dr. John Padfield retired from his position as Chairman of the Board at the end of...



Reykjavik – Icelandic gene-hunter deCode Genetics has emerged from bankruptcy and will continue its genetics research and gene-based diagnostics as a private company, but it will abandon its efforts to develop drugs from its...

Politics / Law, Denmark


When the 2009 United Nations Climate Change Conference ended in December with the “Copenhagen Accord”, the final press release claims that the declaration “was supported by a majority of countries, including amongst them the...

BioPeople, Germany


Frankfurt – Raupach & Wollert-Elmendorff is expanding into the life sciences sector. In January, the respected German advisors for business law announced they had hired Peter Homberg as an Equity Partner. Homberg is a renowned...

Displaying results 341 to 350 out of 1983

< Previous 341-350 Next >

© 2007-2015 BIOCOM


LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...

Product of the week



All Events


Frankfurt am Main (DE)


Stock list

All quotes


  • ADDEX3.28 CHF7.54%
  • FORMYCON29.50 EUR3.91%
  • EPIGENOMICS5.72 EUR3.06%


  • CYTOS0.64 CHF-3.03%
  • VITA 345.65 EUR-2.59%
  • BAYER133.40 EUR-2.56%


  • SYNGENTA423.60 CHF29.8%
  • EVOLVA1.82 CHF19.0%
  • BASILEA131.30 CHF16.1%


  • CYTOS0.64 CHF-34.7%
  • MEDIGENE8.55 EUR-18.2%
  • 4SC4.55 EUR-12.5%


  • WILEX4.07 EUR408.8%
  • FORMYCON29.50 EUR335.1%
  • 4SC4.55 EUR299.1%


  • MOLOGEN4.93 EUR-53.7%
  • PAION2.52 EUR-27.4%
  • BIOFRONTERA2.25 EUR-26.9%

No liability assumed, Date: 28.05.2015

Current issue

All issues